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Gastric cancer is a heterogeneous cancer, making treatment responses difﬁcult to predict.
Here we show that we identify two distinct molecular subtypes, mesenchymal phenotype
(MP) and epithelial phenotype (EP), by analyzing genomic and proteomic data. Molecularly,
MP subtype tumors show high genomic integrity characterized by low mutation rates and
microsatellite stability, whereas EP subtype tumors show low genomic integrity. Clinically, the
MP subtype is associated with markedly poor survival and resistance to standard che-
motherapy, whereas the EP subtype is associated with better survival rates and sensitivity to
chemotherapy. Integrative analysis shows that signaling pathways driving epithelial-to-
mesenchymal transition and insulin-like growth factor 1 (IGF1)/IGF1 receptor (IGF1R) path-
way are highly activated in MP subtype tumors. Importantly, MP subtype cancer cells are
more sensitive to inhibition of IGF1/IGF1R pathway than EP subtype. Detailed characterization
of these two subtypes could identify novel therapeutic targets and useful biomarkers for
prognosis and therapy response.
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Gastric cancer is the third leading cause of cancer-relateddeath and the ﬁfth most commonly diagnosed cancer inthe world1. Although surgery is frequently recommended
for localized gastric cancer2, the beneﬁt from surgery alone is
limited to patients with relatively early-stage disease. To prevent
recurrence and improve the survival rates of patients after sur-
gery, multimodal therapies, including chemoradiation and che-
motherapy, have been established3. However, such treatments
have improved cure rates by only ~10% and have increased
toxicity. Both preoperative chemotherapy and postoperative
chemoradiation chemotherapy have shown beneﬁt over surgery
alone4–6. However, >50% of patients still succumb to their cancer.
Even with the advent of adjunctive therapies, however, the
optimal approach for an individual patient or subset of patients is
difﬁcult to determine3. There is considerable clinicopathologic
heterogeneity among tumors and outcomes among patients
considered to have similar clinical or pathologic disease remain
unpredictable7,8. This inherent clinical heterogeneity is consistent
with the biological differences among patients with gastric cancer.
During the course of tumor progression, cancer cells with an
epithelial origin frequently acquire a mesenchymal phenotype
through epithelial-to-mesenchymal transition (EMT), which is a
physiologic process in which epithelial cells acquire phenotypic,
motile, and invasive characteristics of mesenchymal cells9,10.
EMT can be mediated by many different signaling pathways,
including the transforming growth factor (TGF)-β pathway11.
Although EMT is considered to be one of the biological features
promoting clinical heterogeneity in gastric cancer12–14, the
molecular and genetic characteristics of gastric cancer with an
acquired mesenchymal phenotype and the clinicopathologic sig-
niﬁcance of these characteristics are not fully understood.
In the current study, we used a genome-wide survey of gene
expression data to uncover potential subtypes of gastric cancer
that have distinct biological characteristics associated with prog-
nosis, as well as signaling pathways enriched in each subtype that
could serve as potential therapeutic targets. Here, we report that
gastric cancers with a mesenchymal phenotype are associated
with poor prognosis, markedly low somatic mutation rates and
microsatellite instability (MSI), resistance to standard che-
motherapy, and sensitive to inhibition of IGF1/IGF1R pathway.
Results
Gene signature reﬂecting a mesenchymal phenotype. We ﬁrst
performed unsupervised hierarchical clustering analysis using
gene expression data from 93 human gastric cancer tissue samples
from a Korea University Guro Hospital (KUGH) cohort (Sup-
plementary Table 1) to uncover potential gastric cancer subtypes.
To estimate the degree of heterogeneity among the tumors and
between gastric cancer and non-gastric cancer in the stomach, we
included in the microarray experiments and analysis three sam-
ples of gastrointestinal stromal tumor (GIST), the most common
mesenchymal cancer in the gastrointestinal tract15, that had been
located in the stomach. Unsupervised clustering revealed two
distinct clusters (Fig. 1a): the small (S) cluster and the large (L)
cluster. Interestingly, the three GIST tissue samples were co-
clustered with samples in cluster S. The gastric cancer tissue
samples in cluster S shared a considerable gene expression pat-
terns with GIST tissue samples, indicating that the samples in
cluster S potentially harbored biological characteristics similar to
those of mesenchymal cells. Kaplan–Meier plots and log-rank
tests indicated that patients whose tumor samples fell into the S
cluster had signiﬁcantly lower overall survival (OS) and
recurrence-free survival (RFS) rates than did patients whose
tumor samples fell into the L cluster (P= 0.007 for OS and 0.006
for RFS (Supplementary Table 1); Fig. 1b, c).
We next sought to identify genes whose expression was unique
to the subtype identiﬁed by cluster S, and uncovered 299 genes
with differential expression between the two clusters (Supple-
mentary Fig. 1a and Supplementary Data 1). Gene network
analysis revealed that the TGF-β pathway was the most
signiﬁcantly activated pathway in tumors in cluster S, as
evidenced by increased expression of genes directly regulated by
TGFB1, TGFB3, and SMAD3 (Supplementary Table 2 and
Supplementary Fig. 2). Moreover, SMAD7, an inhibitor of the
TGF-β pathway16, was signiﬁcantly inactivated in the cluster S
genetic signature, offering further supporting evidence that the
TGF-β pathway was activated in tumors in cluster S. The TGF-β
pathway is best known for inducing EMT12, suggesting that
tumors in cluster S lost epithelial characteristics and acquired a
mesenchymal phenotype. Moreover, gene network analysis
revealed that α-catenin, a typical epithelial cell marker in the
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Fig. 1 Hierarchical clustering analysis of gene expression data from the
Korea University Guro Hospital (KUGH) cohort. a Hierarchical clustering of
gene expression data from 93 patients with gastric cancer and 3 patients
with a gastrointestinal stromal tumor (GIST) located in the stomach in the
KUGH cohort (n= 93). Genes with an expression level that had at least a
twofold difference relative to the median value across tissues in at least 15
tissues were selected for hierarchical clustering analysis (3931 gene
features). The data are presented in a matrix format in which each row
represents an individual gene and each column represents a tissue sample.
Each cell in the matrix represents the expression level of a gene feature in
an individual tissue sample. The red and green coloring in the cells reﬂects
relatively high and low expression levels, respectively, as indicated in the
scale bar (log2 transformed scale). b, c Kaplan–Meier plots of the two
gastric cancer clusters in the KUGH cohort (n= 93). The three patients
with GIST were excluded for plotting. P values were obtained using the log-
rank test. The + symbols indicate censored data. EP epithelial phenotype,
MP mesenchymal phenotype, OS overall survival, RFS recurrence-free
survival
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gut17, was the most signiﬁcantly decreased RNA in tumors in
cluster S (Supplementary Table 2). Given this ﬁnding, together
with the similarity of the gene expression pattern in cluster S to
that of the mesenchymal GIST samples, we referred to tumors in
cluster S as mesenchymal phenotype (MP) and those in cluster L
as epithelial phenotype (EP) gastric cancers (“MP subtype” and
“EP subtype” hereafter).
Validation of the MP subtype and its prognostic signiﬁcance.
After identifying the MP genomic signature reﬂecting EMT and
demonstrating its association with poor prognosis in patients
with gastric cancer, we sought to validate the association of the
MP subtype with prognosis in independent patient cohorts. For
this validation, we used gene expression data from the Yonsei
University Severance Hospital (YUSH) cohort (n= 65; Supple-
mentary Table 1 and Fig. 2a). When patients in the YUSH cohort
were stratiﬁed according to MP or EP subtype by the Bayesian
compound covariate predictor (BCCP) algorithm, Kaplan–Meier
plots showed signiﬁcant differences in OS (P= 0.001 by log-rank
test) and RFS (P= 0.003 by log-rank test) rates between patients
with the two different subtypes of tumors (Fig. 2b and Supple-
mentary Fig. 3a).
To further test the robustness of the MP genetic signature and
prognostic relevance of the two subtypes, we generated gene
expression data from another independent cohort (Kosin
University College of Medicine (KUCM) cohort, n= 109;
Supplementary Table 1). The prognosis for patients with MP
subtype tumors was signiﬁcantly poorer than for those with EP
subtype tumors (P < 0.001 by log-rank test for both OS and RFS;
Fig. 2c and Supplementary Fig. 3b). When we applied the MP
signature in two independent large cohorts of patients (Samsung
Medical Center (SMC) cohort, n= 432 and Asian Cancer
Research Group (ACRG) cohort, n= 300; Supplementary Table 1)
18,19, we again found that patients with MP subtype tumors had
signiﬁcantly shorter OS and RFS rates than did those with EP
subtype tumors (Fig. 2d, e and Supplementary Fig. 3c, d, P < 0.001
for both OS and RFS). We also applied the MP signature in
patients with different ethnic backgrounds (white and Hispanic)
from a cohort at The University of Texas MD Anderson Cancer
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Fig. 2 Construction of prediction models in the validation cohorts. a A schematic overview of the strategy used to construct prediction models and evaluate
predicted outcomes on the basis of gene expression signatures. EP epithelial phenotype, MP mesenchymal phenotype, BCCP Bayesian compound covariate
predictor, SVM support vector machine, LOOCV leave-one-out cross-validation, YUSH Yonsei University Severance Hospital, KUCM Kosin University
College of Medicine, SMC Samsung Cancer Research Institute, ACRG Asian Cancer Research Group, MDACC The University of Texas MD Anderson
Cancer Center. b–f Kaplan–Meier plots of overall survival (OS) in patients with EP or MP subtype gastric cancer predicted by BCCP in the YUSH cohort (b),
KUCM cohort (c), SMC cohort (d), ACRG (e), and MDACC cohort (f). P values were obtained using the log-rank test. The + symbols in the panels indicate
censored data
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Center (MDACC cohort; n= 40; Supplementary Table 1).
Consistent with results from the other cohorts, in which most
patients were ethnically Asian, OS rates in patients in the
MDACC cohort with MP subtype tumors were signiﬁcantly lower
(P= 0.01 by log-rank test) than in those with EP subtype tumors
(Fig. 2f). In addition, when a support vector machine (SVM)
algorithm was applied to the same gene expression data as an
independent prediction model, we observed highly concordant
predicted outcomes from SVM and the BCCP as evidenced by a
signiﬁcant difference in prognosis between SVM-predicted
subtypes and a signiﬁcantly high Cohen’s kappa coefﬁcient in
all tested cohorts (Supplementary Fig. 4). Taken together, these
results demonstrated the robustness of MP signature regardless of
differences in ethnicity and prediction algorithms.
To evaluate the prognostic value of the MP signature in
combination with other clinical variables, we next carried out
univariate and multivariate Cox proportional hazards regression
analyses with combined clinicopathologic variables in a pooled
cohort (KUGH, YUSH, KUCM, SMC, and ACRG cohorts
combined; n= 999). In addition to depth of tumor invasion,
lymph node invasion, distant metastasis, and American Joint
Committee on Cancer (AJCC) stage, which are well-known
prognostic factors, MP or EP subtype was a signiﬁcant predictor
of RFS in the univariate analysis (Supplementary Table 3). When
we included all relevant clinical variables in a multivariate Cox
regression analysis, we found that MP or EP subtype remained a
signiﬁcant prognostic factor (MP subtype hazard ratio (HR) 1.7,
95% conﬁdence interval (CI) 1.36–2.2, and P= 2.7 × 10−6 by
likelihood ratio test for RFS; Supplementary Table 3).
We then tested the prognostic independence of the MP or EP
subtype against current staging systems. When patients with
different AJCC disease stages were stratiﬁed by tumor subtype,
the subtype successfully identiﬁed high-risk patients at all AJCC
stages (Fig. 3). Taken together, these ﬁndings suggest that the MP
signature retains its prognostic relevance even after classic
clinicopathologic prognostic features have been taken into
account.
Resistance of the MP subtype to chemotherapy. Because more
than half of patients in the KUGH, YUSH, and KUCM cohorts
had received adjuvant chemotherapy, we next sought to deter-
mine whether each subtype was also associated with a difference
in clinical beneﬁt from adjuvant chemotherapy. Because patients
with locally advanced gastric cancer have been shown to beneﬁt
most from adjuvant chemotherapy, we performed a subset ana-
lysis of patients in the KUGH, YUSH, and KUCM cohorts with
AJCC stage II, III, or IV disease without distant metastasis (n=
180). Of the 180 patients, 132 received adjuvant chemotherapy.
These patients were divided by tumor subtype (MP or EP), and
the difference in RFS rates was independently assessed. Adjuvant
chemotherapy was associated with signiﬁcantly increased RFS
rates in patients with EP subtype tumors (3-year RFS rate of
70.1% for those who received chemotherapy compared with
43.4% for those who did not; P= 0.003 by log-rank test; Fig. 4b).
The HR for recurrence among those who received adjuvant
chemotherapy was 0.42 (95% CI 0.22–0.8, P= 0.004 by likelihood
ratio test). However, no beneﬁt from adjuvant chemotherapy was
observed among patients with MP subtype tumors (3-year RFS
rate of 44.8% for those who received chemotherapy compared
with 42.1% for those who did not; P= 0.98 by likelihood ratio
test; Fig. 4c).
We also carried out an interaction test to assess the true
difference (heterogeneous treatment effect) between the two
tumor subtypes in terms of the impact of adjuvant chemotherapy.
When the Cox regression model was applied, the interaction of
the MP and EP subtypes with adjuvant chemotherapy reached
signiﬁcance (P= 0.01 by likelihood ratio test; Fig. 4d), demon-
strating that patients with EP subtype tumors beneﬁt from
adjuvant chemotherapy more than patients with the MP subtype.
Genomic and proteomic landscape of the two subtypes. We
next investigated the molecular characteristics of the MP and EP
subtypes using genomic and proteomic data recently generated
from gastric cancer tissues (n= 262) from The Cancer Genome
Atlas (TCGA) project20. Analysis of these data revealed that the
somatic mutation rate was signiﬁcantly lower in MP subtype
tumors than in EP subtype tumors (P= 2.4 × 10−8 by Student’s
t-test; Fig. 5), suggesting that the DNA repair system is relatively
intact in MP subtype cancer cells. In EP subtype tumors, con-
sistent with a higher mutation rate, MLH1, a DNA mismatch
repair gene, was signiﬁcantly silenced through methylation of its
promoter regions. In contrast, among MP subtype tumors, with a
low mutation rate and intact MLH1 activity, we did not observe
the MSI that is typical in colon cancer with mutations in the DNA
mismatch repair genes and hypermutations21. In addition, the
MP subtype was weakly associated with a lack of Epstein–Barr
virus (EBV) infection, which is known to be associated with better
prognosis22,23.
We next analyzed proteomic data generated using reverse
phase protein arrays from TCGA tumor samples. Consistent with
our gene expression data, E-cadherin and α-catenin, two of the
most important epithelial adhesion proteins in epithelial cells17,
Stage I Stage II Stage III Stage IV
MP
EP
MP
EP
MP
EP
MP
EP
0 50 100 150
RFS (months)
0 40 80 120
RFS (months)
P = 2.8 x 10–4 P = 0.001
0 50 100 150
0.0
0.2
0.4
0.6
0.8
1.0
0.0
0.2
0.4
0.6
0.8
1.0
0.0
0.2
0.4
0.6
0.8
1.0
0.0
0.2
0.4
0.6
0.8
1.0
RFS (months)
Pr
ob
ab
ilit
y
0 50 100 150
RFS (months)
P = 1.3 x 10–4 P = 0.004
Fig. 3 Prognostic signiﬁcance of mesenchymal phenotype (MP) independent of AJCC stages. When patients were stratiﬁed according to stages in the
pooled cohort (KUGH, YUSH, KUCM, SMC, and ACRG in total of n= 999), MP remained associated with poor prognosis regardless of stages. P values
were obtained using the log-rank test. The + symbols in the panels indicate censored data. EP epithelial phenotype, MP mesenchymal phenotype, RFS
recurrence-free survival
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were among the most downregulated proteins (Supplementary
Fig. 5) in MP subtype tumors, strongly suggesting that MP
subtype tumors lose epithelial characteristics. The MP subtype
was also associated with high expression of MYH11 (smooth
muscle myosin, heavy chain 11), RICTOR, and CAV11 (caveolin
11), which are markers for mesenchymal lineage or are involved
in EMT24–28. Taken together with our gene expression data, these
ﬁndings strongly suggest that MP subtype tumors appears to have
an increased potential for invasion and metastasis.
We also assessed genome-wide copy number alterations in the
two subtypes. Although both subtypes shared highly similar copy
number alterations across chromosomes, the magnitude of copy
number loss was substantially lower in MP subtype tumors
(Supplementary Fig. 6), suggesting that MP subtype tumors have
a more stable genome. Analysis of RNA-sequencing data from
TCGA tumor samples also uncovered signiﬁcantly upregulated
microRNAs (miRNAs) in MP subtype tumors. miR-490, which is
best known for promoting EMT29, showed the highest level of
upregulation among MP subtype tumors (Supplementary Fig. 7),
providing further supporting evidence that MP subtype tumors
have mesenchymal characteristics.
When we tested for an association between MP or EP subtype
and Lauren histologic classiﬁcation30, we found that diffuse
histologic type was signiﬁcantly more common among MP
subtype tumors (61.9% of MP subtype tumors and 38.1% of EP
subtype tumors; P= 1.5 × 10−7 by χ2 test; Supplementary
Table 4), suggesting a potential connection between histologic
and molecular subtypes. Consistent with the diffuse type having a
higher stromal or non-tumor content, MP subtype has higher
non-tumor content than EP subtype (Supplementary Fig. 8a).
Likewise, estimation of non-tumor content using CIBERSORT31
also showed a higher percentage of non-tumor cells in MP
subtype (Supplementary Fig. 8b).
Biological insights of the two subtypes. We next identiﬁed genes
whose expression patterns were speciﬁc to the MP subtype and
were conserved in gastric cancer tissue samples from ﬁve cohorts
(KUGH, YUSH, KUCM, TCGA, and ACRG), as described in the
Methods. Expression of 605 genes was signiﬁcantly different
between MP and EP subtype tumors in all ﬁve cohorts (Fig. 6).
Because MP subtype has higher non-tumor content, we estimated
contribution of non-tumor cells to gene expression level by
removing the proportion of gene expression from non-tumor
cells (see Online Methods). When the contribution of non-tumor
cells was removed, the difference between MP and EP subtype
was not substantially changed (Supplementary Fig. 8c). Likewise,
adjustment of gene expression data with CIBERSORT showed
similar results (Supplementary Fig. 8d), suggesting that non-
tumor or stromal cells were not key contributor of gene expres-
sion difference between two subtypes.
When the 605 differentially expressed genes were ranked
according to expression ratios between MP and EP subtype
tumors, members of the secreted frizzled-related protein (SFRP)
family, key inhibitors of WNT ligands32, were among the top-
ranked genes. Of the ﬁve known members of the SFRP family,
four SFRPs (SFRP1, SFRP2, SFRP3 (also known as FRZB), and
SFRP4) were signiﬁcantly downregulated (P < 0.001 by Student’s
t-test and <3-fold) in EP subtype tumors, indicating that the
WNT pathway might be highly activated in EP subtype tumors
(Supplementary Fig. 9a). Expression of these genes was not
signiﬁcantly different after adjustment for non-tumor cell effects
(Supplementary Fig. 10). Downregulation of SFRPs was mediated
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by hypermethylation of the promoter regions of these genes, as
evidenced by increased methylation in EP subtype tumors
(Supplementary Fig. 9b) and signiﬁcant inverse correlation
between promoter methylation and messenger RNA (mRNA)
expression of all four SFRPs (Supplementary Fig. 11). Down-
regulation of SFRPs in EP subtype was further validated in
another cohort (YUSH, Supplementary Figs. 12 and 13).
In addition, expression of GLI transcription factors (GLI1,
GLI2, and GLI3), which are key transcription factors of the
hedgehog pathway33, was signiﬁcantly upregulated in MP subtype
tumors, suggesting potential activation of the hedgehog pathway
in MP subtype tumors. Indeed, gene network analysis revealed
that the hedgehog pathway was highly activated in MP subtype
tumors (Supplementary Fig. 14). Consistent with previous
analysis, gene network analysis of the 605 conserved genes also
revealed that the TGF-β pathway was signiﬁcantly activated in
MP subtype tumors (Supplementary Fig. 15).
IGF1 and IGF1R pathway as therapeutic target for MP sub-
type. Most interestingly, expression of IGF1 was signiﬁcantly
upregulated in MP subtype tumors (Fig. 6) with signiﬁcance
remaining the same even after adjustment of expression data for
non-tumor cell effect (Supplementary Fig. 10). To uncover
potential mechanisms for upregulation of IGF1 in MP subtype
tumors, we analyzed genomic copy number and promoter
methylation of the IGF1 gene. Of the 70 MP subtype tumor
samples from TCGA, 11 showed ampliﬁcation of the IGF1 gene,
and expression of IGF1 in these tumors was signiﬁcantly higher
than in normal tissue and in EP subtype tumors (Fig. 7a, b). The
promoter region of IGF1 was signiﬁcantly hypomethylated in the
remaining MP subtype tumors (Fig. 7a, c). Consistently, mRNA
expression of IGF1 was inversely correlated with promoter
methylation (Fig. 7d). Hypomethylation of the IGF1 promoter in
MP subtype was further validated by pyrosequencing of promoter
region in tumors from the YUSH and KUCM cohorts (Supple-
mentary Fig. 16a). In good agreement with the TCGA data,
methylation status was inversely correlated with expression of
mRNA (Supplementary Fig. 16b), further supporting
methylation-mediated regulation of IGF1 expression in MP
subtype tumors. Taken together, these data strongly suggest that
upregulation of IGF1 in MP subtype tumors might contribute to
early recurrence and resistance to chemotherapy.
Since analysis of genomic data from multiple cohorts suggested
activation of the IGF1 pathway in MP subtype, we assessed
activation status of the IGF1 receptor (IGF1R) in gastric cancer
tissues with western blot experiments. In good agreement with
our analysis, IGF1R was signiﬁcantly more activated (phosphory-
lated) in MP subtype than in EP subtype as evidenced by higher
phosphorylation of the receptor in MP (P= 3.2 × 10−4 by
Student’s t-test, Fig. 7e, f). We next tested if MP gastric cancer
cells were more sensitive to inhibition of IGF1R. Gastric cancer
cell lines were ﬁrst grouped according to expression of IGF1. Of
the six cell lines examined, Hs746T, SNU1, and MKN74
expressed IGF1 (MP-like), while the remainders (MKN28,
MKN45, and SNU16) lacked expression of IGF1 (EP-like)
(Fig. 8a). In good agreement with this, phosphorylation of IGF1R
in cell lines correlated with IGF1 expression (Fig. 8b). Treatment
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retrieved from The Cancer Genome Atlas project database and analyzed (n= 262). Tumors with greater than 11.4 mutations/Mb were classiﬁed as
hypermutated tumors. ALL P values were obtained using χ2 tests except for mutation rates. P values for mutation rates were obtained using Student’s t-test
(two-sided). b Mutational landscape of two subtypes in TCGA cohort. Most frequently mutated genes in TCGA data are presented (20 genes)
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with the demethylation agent 5-azacytidine (5-AzaC) restored
expression of IGF1 in two of EP-like gastric cancer cells (MKN28
and SNU16, Supplementary Fig. 17). Furthermore, promoter
regions of IGF1 were concomitantly demethylated upon treat-
ment of 5-AzaC (Supplementary Fig. 18), supporting promoter
hypomethylation as one of the mechanisms for activation of the
IGF1/IGF1R pathway in gastric cancer. When MP signature-
based BCCP model was applied to gene expression data from
these cell lines, Hs746T and SNU1 were predicted as MP subtype
while MKN45 and SNU16 were predicted as EP subtype
(Supplementary Fig. 19), further supporting molecular correla-
tion between IGF1 expression and MP subtype in gastric cancer
cells. In good agreement with our hypothesis, three MP-like cell
lines with high IGF1 expression were signiﬁcantly more sensitive
to treatment of linsitinib in a dose-dependent manner (Fig. 8c).
To explore this in a mouse model, we carried out a mouse
xenograft experiment with SNU1 cells. Tumor growth was
signiﬁcantly delayed by linsitinib treatment (Fig. 8d), and tumor
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Fig. 6 Subtype-speciﬁc gene expression patterns conserved in ﬁve cohorts of patients with gastric cancer. a Venn diagram of genes with expression that
differed signiﬁcantly between the mesenchymal phenotype (MP) and epithelial phenotype (EP) subtypes in ﬁve different cohorts (KUCM Kosin University
College of Medicine, KUGH Korea University Guro Hospital, TCGA The Cancer Genome Atlas, YUSH Yonsei University Severance Hospital, ACRG Asian
Cancer Research Group). Gene expression differences were considered statistically signiﬁcant at P < 0.001 by Student’s t-test. This stringent signiﬁcance
threshold was used to limit the number of false-positive ﬁndings. Expression of only 605 genes was upregulated or downregulated in all ﬁve cohorts. b
Expression patterns of selected genes. The colored bars at the top of the heat map represent samples as indicated
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weight remained low (Fig. 8e, f). Consistently, growth of Hs746T
tumors was also signiﬁcantly reduced by linsitinib treatment
(Supplementary Fig. 20). Notably, treatment of linsitinib
signiﬁcantly downregulated AKT and extracellular signal-
regulated kinase (ERK) signaling (Supplementary Fig. 20d, e),
the key downstream effectors of IGF1R. Together with data from
cell lines, these results clearly demonstrate that MP gastric tumors
are sensitive to inhibition of IGF1R.
Similarity to other molecular subtypes. Since MP subtype has
clinical and molecular characteristics similar to previously
recognized genomic diffuse (G-DIF) tumors in intrinsic sub-
types34, we compared two molecular subtypes after stratifying
patients according to intrinsic genomic signature (G-DIF or
genomic intestinal [G-INT] subtype). For convenience of com-
parison, we pooled three Illumina platform cohorts (KUGH,
YUSH, and KUCM) and renamed them: KYK cohort. Consistent
with a previous report34, patients in the G-DIF subtype had a
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poor prognosis in all three cohorts as evidenced by signiﬁcantly
shorter RFS (Supplementary Fig. 21). A vast majority of patients
in MP subtypes were G-DIF subtype, although it represents much
larger patient population (Supplementary Fig. 21a), suggesting
that MP subtype is a subset of G-DIF subtype. Interestingly,
prognosis of patients in MP subtype were signiﬁcantly worse than
those in the remaining G-DIF subtypes in all three cohorts
(Supplementary Fig. 21b), suggesting difference between MP and
G-DIF subtypes. Furthermore, expression of IGF1, the most
distinctive characteristic of MP subtype, is signiﬁcantly higher in
MP subtype than in G-DIF subtype (Supplementary Fig 22).
These data suggested that MP subtype is biologically and clini-
cally different from G-DIF subtype, although they share some
similarity. Furthermore, only a few genes were shared by the two
prognostic expression signatures (Supplementary Fig. 23). Inter-
estingly, MP subtype also shared some clinical features with
previously identiﬁed EMT subtype from ACRG study19 as
demonstrated by that EMT subtype is a subset of MP subtype and
its survival pattern is very similar to MP subtype (Supplementary
Fig. 24).
MP subtype is also similar to genomically stable (GS) subtype
that was identiﬁed in a recent TCGA gastric cancer study20. In
TCGA cohort, patients in MP subtype were divided into EBV
(n= 4), MSI (n= 6), chromosomal instability (n= 22), and GS
(n= 38) subtypes (Supplementary Table 5). Nonexclusive overlap
between two subtypes indicate that MP subtype may be different
from GS subtype although they share some molecular
characteristics.
Discussion
Using a series of independent but complementary approaches, we
found that MP subtype gastric cancer has distinctive genetic and
epigenetic alterations that are associated with poor prognosis and
resistance to chemotherapy (Fig. 9). The existence of the MP
subtype of gastric cancer is strongly supported by several lines of
evidence in our study. First, the global gene expression patterns of
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MP subtype tumors were highly similar to those of GIST, a
mesenchymal cancer. Second, signaling pathways that drive EMT,
including the TGF-β pathway12 and the hedgehog pathway35,
were highly activated in MP subtype tumors. Third, expression of
E-cadherin and α-catenin was signiﬁcantly reduced in MP sub-
type tumors. Fourth, expression of EMT-promoting proteins or
miRNAs, including MYH11, RICTOR, CAV11, and miR-490,
was signiﬁcantly increased in MP subtype tumors. Lastly, recur-
rence rates reﬂecting clinical consequences of EMT9–11 were
signiﬁcantly higher in patients with MP subtype tumors.
Our data clearly demonstrate the clinical signiﬁcance of the
two subtypes as tested and validated in six independent cohorts
with a total of 1039 patients. In addition to the prognostic dif-
ferences between the two subtypes, we found differences in
response to standard treatments. Subset analysis of patients with
available chemotherapy data strongly suggested that only EP
subtype is associated with beneﬁt from adjuvant chemotherapy.
In patients with advanced disease, 5-ﬂuorouracil–based che-
motherapy was associated with improved outcomes for patients
with EP subtype tumors, whereas this chemotherapy provided no
beneﬁt for those with MP subtype tumors.
Low sensitivity of MP subtype tumors to chemotherapy is
consistent with our observation that MP subtype tumors are
similar to GIST, which is associated with almost no beneﬁt from
adjuvant chemotherapy. GIST partial response rates to systemic
chemotherapy have been shown to be less than 15%36,37. Previous
studies have demonstrated a signiﬁcant correlation between
genome instability and increased sensitivity to cytotoxic che-
motherapy in ovarian cancer, strongly suggesting that the high
genomic instability in EP subtype tumors might contribute to
their relatively higher sensitivity to adjuvant chemotherapy.
Taken together, our results strongly indicate that the two
subtypes of gastric cancer are biologically distinct and might
require different optimal clinical courses of treatment.
One of the most striking biological characteristics of EP sub-
type tumors was the concordant downregulation of all SFRPs,
whose best-known function is inhibition of the WNT pathway32,
suggesting that the WNT pathway might contribute to the
development and progression of EP subtype gastric tumors. Our
integrated analysis clearly demonstrated that activation of the
WNT pathway was mediated by hypermethylation of SFRP
promoters. This observation is consistent with previous studies
demonstrating that the WNT pathway is regulated by promoter
methylation of SFRPs in gastric cancer cell lines38–41 and pro-
vides further evidence that inactivation of SFRPs by promoter
methylation is a clinically important epigenetic alteration in
gastric cancer. These ﬁndings suggest that patients with EP sub-
type gastric cancer may beneﬁt from treatment with DNA
methylation inhibitors such as decitabine and azacitidine40.
Our data also demonstrated that IGF1/IGF1R pathway is
highly activated in MP subtype through demethylation of IGF1
promoter sequences. More importantly, MP subtype gastric
cancer cells were more sensitive to inhibition of IGF1/IGF1R
pathway. IGF1/IGF1R pathway has been considered as key
therapeutic targets for many cancers42,43. Although more than 10
IGF/IGF1R inhibitors have entered clinical trials44, many large
clinical trials involving patients with non-small-cell lung cancer,
breast cancer, and pancreatic cancer failed to show signiﬁcant
clinical beneﬁt45–47. However, even among these unsuccessful
trials, there are subsets of patients who have obtained beneﬁt
from IGF1R inhibition48. Since our data indicated that beneﬁt of
inhibiting IGF1/IGF1R pathway might be limited to MP subtype
gastric cancer, possible reasons for current failure might be due to
the lack of use of patient enrichment by biomarkers in the trials.
Thus, our study may provide an opportunity to develop marker-
based targeted therapy for gastric cancer which will increase
patient beneﬁt.
Our study has some limitations such as retrospective nature of
clinical data. We cannot also rule out the possibility that cancer
cells may induce expression of IGF1 from stromal cells by sti-
mulating tumor microenvironment as tumors in MP subtype
have higher fraction of non-tumor cells. Therefore, further in-
depth examination of tumor microenvironment in both subtypes
will be necessary in future studies.
In conclusion, we have identiﬁed two new subtypes of gastric
cancer that are associated with signiﬁcantly different survival
outcomes. The MP genetic signature can be used to identify not
only patients at high risk for recurrence (MP subtype), but also
patients who would beneﬁt from adjuvant chemotherapy (EP
subtype) or targeted therapy (MP). Our data also make a case for
targeted therapy as adjuvant therapy for MP gastric cancer
patients. Further validation will be necessary before testing for the
MP genetic signature can be implemented in routine clinical
practice. Nevertheless, the validation of our ﬁndings in several
independent patient cohorts and the fact that our two subtypes
reﬂect biological characteristics associated with sensitivity or
resistance to standard chemotherapy or targeted therapy indicates
that our ﬁndings provide an opportunity to develop rational
therapy recommendations. The association of the EP subtype
with beneﬁts from currently available standard treatments and
the MP subtype with potential targeted treatments, if conﬁrmed
in prospective studies, could improve patient selection for these
treatments.
Methods
Patients and samples. We obtained fresh-frozen tumor specimens and clinical
data from patients with gastric cancer who underwent gastrectomy as primary
treatment at the KUGH (n= 93), YUSH (n= 65, or KUCM (n= 109), South
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Korea, between 1999 and 2006. Frozen biopsy specimens of tumor tissues endos-
copically collected before treatment from 40 patients with gastric cancer (treated
from 2002 through 2010) were obtained from the fresh-frozen tissue bank of The
University of Texas MD Anderson Cancer Center (the MDACC cohort). As an
external validation set, we used additional tumor specimens collected from the
SMC (n= 432) and ACRG (n= 300), as described in a previous study18,19. Clinical
data of patients in all cohorts are available in Supplementary Data 2.
All samples were collected after written informed consent was obtained from
patients, and the study was approved by the Institutional Review Board of The
University of Texas MD Anderson Cancer Center (Houston, TX), KUGH (Seoul,
Korea), YUSH (Seoul, Korea), KUCM (Busan, Korea), or SMC (Seoul, Korea).
Clinical data were obtained retrospectively. OS was deﬁned as the time from
surgery to death, and RFS was deﬁned as the time from surgery to the ﬁrst
conﬁrmed recurrence. Data were censored when a patient was alive without
recurrence at last contact. Of the 267 patients in the KUGH, YUSH, and KUCM
cohorts, 155 had received standard adjuvant chemotherapy (either single-agent 5-
ﬂuorouracil or a combination of 5-ﬂuorouracil and cisplatin/oxaliplatin,
doxorubicin, or paclitaxel). All patients in the MDACC cohort received
preoperative (neoadjuvant) chemotherapy or chemoradiation therapy. All patients
in the SMC cohort received homogenous treatment with the INT-0116 regimen (5-
ﬂuoouracil/leucovorin and radiation) as adjuvant treatment18. Both OS and RFS
data were available for patients in the KUGH, YUSH, KUCM, SMC, and ACRG
cohorts, but only OS data were available for patients in the MDACC cohort.
Microarray experiments were performed with 267 samples of surgically
removed frozen gastric cancer tissue (KUGH, YUSH, and KUCM cohorts),
40 samples of tumor biopsies (MDACC cohort), and 12 samples of surrounding
non-tumor tissue. In addition, frozen samples of GIST tissue from the KUGH
(three samples) were included in the microarray experiments. Patient
characteristics for all cohorts are summarized in Supplementary Table 1. Data from
the KUGH cohort were used to explore and identify potential prognostic signatures
(exploration cohort, n= 93) and patient data from the remaining cohorts were
used for validation of the prognostic signature (validation cohorts, n= 946)
Gene expression data. All of the experiments and analyses were conducted in the
Department of Systems Biology at MD Anderson. Gene expression data from 307
patients with gastric cancer were generated by hybridizing labeled RNAs to human
expression BeadChips (Human HT-12 v3.0; Illumina, San Diego, CA) containing
48,803 gene features. Brieﬂy, total RNA was extracted from the fresh-frozen tissues
using a mirVana RNA Isolation Labeling Kit (Ambion, Inc., Austin, TX). We used
500 ng of total RNA for labeling and hybridization, according to the manufacturer’s
protocols. Gene expression data from the SMC cohort were generated using
HumanRef-8 WG-DASL v3.0 (Illumina) that contained a subset (24,526 gene
features) of probes in Human HT-12. Gene expression data from the ACRG cohort
were generated using Affymetrix Human Genome U133 Plus 2.0 Array. The
microarray data were normalized using the quantile normalization method in the
Linear Models for Microarray Data package in the R language environment49. The
expression level of each gene was transformed into a log2 base before further
analysis. Primary microarray data are available in the Gene Expression Omnibus
database of the National Center for Biotechnology Information (accession numbers
GSE26899 for KUGH, GSE26901 for KUCM, GSE13861 for YUSH, GSE28541 for
MDACC, GSE26253 for SMC, and GSE66229 for ACRG). Gene expression data
from gastric cancer cell lines were obtained from GEO database (GSE22183).
Genomic data from the TCGA cohort. Genomic data from the TCGA gastric
cancer cohort were downloaded from the TCGA data portal site (http://
cancergenome.nih.gov/) and processed as described in previous studies20,21,50–54.
Because mRNA expression data were available for 262 tumor tissues, all analysis
with other data sets was limited to samples with available mRNA data. We ana-
lyzed 262 samples for methylation, 240 for miRNA, 260 for copy number altera-
tion, and 257 for exome sequencing. Because most of the tissues in the TCGA
cohort were recently collected, follow-up time of the patients in the TCGA cohort
was very short and not sufﬁcient enough for survival analysis. These patients were
not included in survival analysis.
Reverse phase protein arrays (RPPA). RPPA data were generated at MD
Anderson. Brieﬂy, protein was extracted using RPPA lysis buffer (1% Triton X-100,
50 nmol/L Hepes (pH 7.4)), 150 nmol/L NaCl, 1.5 nmol/L MgCl2, 1 mmol/L EGTA,
100 nmol/L NaF, 10 nmol/L NaPPi, 10% glycerol, 1 nmol/L phenylmethylsulfonyl
ﬂuoride, 1 nmol/L Na3VO4, and 10 Ag/mL aprotinin) from human tumors and
RPPA was performed as described previously20,21,50,51. Tumor lysates were
adjusted to 1 μg/μL concentration, diluted in ﬁvefold serial dilutions with lysis
buffer, and printed on nitrocellulose-coated slides (Grace Bio-Labs, Bend, OR).
Slides were probed with 191 validated primary antibodies followed by corre-
sponding secondary antibodies (goat anti-rabbit IgG, goat anti-mouse IgG, or
rabbit anti-goat IgG). Signal was captured using diaminobenzidine colorimetric
reaction and normalized by using the ﬁtted curve (“supercurve”) approach53. In
total, 255 samples were included in the analysis.
Statistical analysis. BRB-Array Tools (National Institutes of Health) was pri-
marily used for all statistical analyses55. Cluster analysis was performed using
Cluster and Treeview v3.0 (ref. 56). We identiﬁed genes whose expression was
unique to the S cluster (MP subtype) by cross-comparing gene lists from inde-
pendent statistical tests. We ﬁrst generated two different gene lists by applying 2-
sample t-tests (P < 0.001). Gene list X represented genes that were differentially
expressed between the S cluster (MP subtype) and L cluster (EP subtype), and gene
list Y represented genes that were differentially expressed between the S cluster
(MP subtype) and non-tumor gastric surrounding tissues from patients with gastric
adenocarcinoma (Supplementary Fig. 1). By applying an additional threshold
cutoff (twofold difference) to common genes in the two gene lists, we identiﬁed 299
genes whose expression patterns were speciﬁc to the S cluster (MP subtype) and
that were potential markers for predicting prognosis. Multivariate Cox propor-
tional hazards regression analysis was used to evaluate independent prognostic
factors associated with survival, and gene signature, tumor stage, and pathologic
characteristics were used as covariates. To assess the strength of the interaction
between the two subtypes and adjuvant chemotherapy, a Cox proportional hazards
model was ﬁtted to data from patients in the pooled cohort. The model included
three other covariates from the primary analysis (sex, age, and American Joint
Committee on Cancer stage). All statistical analyses were conducted in the R
language environment (http://www.r-project.org).
Prediction models for validation of the MP signature. Prediction of patient class
in independent cohorts was done as described previously57–62. Brieﬂy, gene
expression data in the training set (KUGH cohort) were combined to form a
classiﬁer according to Bayesian compound covariate predictor (BCCP)63, and the
robustness of the classiﬁer was estimated using a misclassiﬁcation rate determined
during the leave-one-out cross-validation (LOOCV) in the training set. When a
classiﬁer was applied to the independent validation sets (YUSH, KUCM, MDACC,
SMC, and ACRG cohorts), prognostic signiﬁcance was estimated using
Kaplan–Meier plots and log-rank tests between two predicted subtypes of patients.
After LOOCV, sensitivity and speciﬁcity of the prediction models were estimated
using the fraction of samples correctly predicted. Speciﬁcity for correctly predicting
the MP subtype by BCCP was 0.924, and sensitivity was 0.963. SVM algorithm was
applied to gene expression data to test the robustness of the MP signature. Spe-
ciﬁcity and sensitivity of SVM predictor for MP subtype was 0.97 and 0.963,
respectively. BCCP classiﬁer was also applied to gene expression data from gastric
cancer cell lines (GSE22183). Of the six cell lines used in drug sensitivity test, gene
expression data were only available for four cell lines.
Previously deﬁned G-IDF/G-INT gene expression signature (171 genes)34 and
BCCP algorithm were applied to gene expression data to stratify patients into G-
DIF and G-INT subtypes.
Selection of conserved MP-speciﬁc gene expression patterns. Although the
299 gene expression signature was robust enough to identify patients with the MP
and EP subtypes in all 6 cohorts (n= 1039 total), the number of genes was not
sufﬁcient enough to develop a sophisticated gene network analysis, because we
applied an extremely stringent cutoff (P < 0.001 by Student’s t-test and twofold
difference) to avoid any potential false-positive results during signature-based
prediction. Thus, to explore biological characteristics of the MP and EP subtypes,
we selected genes whose expression patterns were conserved in the ﬁve cohorts
(KUGH, YUSH, KUCM, TCGA, and ACRG). Gene expression data from the SMC
cohort were not included because they were not generated using a full genome
microarray and had only a limited number of genes. Likewise, gene expression data
from the MDACC cohort were not included owing to small sample size. Gene lists
K, Y, Q, T, and A (Fig. 6a) represented genes that were differentially expressed
between the MP and EP subtypes in the KUGH, YUSH, KUCM, TCGA, ACRG
cohorts, respectively. Expression of 605 gene features was signiﬁcantly different
between the MP and EP subtypes in all 5 cohorts.
Bioinformatics analysis. Ingenuity Pathways Analysis (Ingenuity Systems, www.
ingenuity.com) was used for gene set enrichment analysis and gene network
analysis. Gene set enrichment analysis was carried out to identify the most sig-
niﬁcant gene sets associated with disease process, molecular and cellular functions,
and normal physiological and developmental conditions in selected genes as
described in the instructions from the Ingenuity Systems. The signiﬁcance of over-
represented gene sets was estimated using the right-tailed Fisher's exact test. Gene
network analysis was carried out using a global molecular network developed from
information contained in the Ingenuity Knowledge Base.
To estimate stromal content in tumor mass, we used analytical platform
CIBERSORT (https://cibersort.stanford.edu/) that can quantify relative levels of the
abundances of distinct cell types in a mixed cell population31. Mean gene
expression data from tumors and surrounding tissues were used as reference
(signature gene data) for tumor cell and normal gastric cells and individual tumor
data were considered as mixture data as instructed. Analyses were done with 100
permutations with default statistical parameters. Estimated percentage of stromal
cells in tumor mass ranged from 0 to 72%.
Histologically examined stromal cell percentage and CIBERSORT predicted
stromal cell percentage were used to estimate contribution of stromal cells to gene
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expression data from tumor mass. Contribution of stromal cells in gene expression
data from tumor mass were removed by multiplying tumor cell percentages (0 to
1 scale) to gene expression data.
Cell culture and 5-AzaC treatment. Hs746T cell line was cultured in Dulbecco’s
modiﬁed Eagle’s medium with high glucose and 4 mM glutamine (Invitrogen,
Carlsbad, CA, USA). SNU1, MKN74, MKN28, MKN45, and SNU16 cell lines were
cultured in RPMI 1640 (Invitrogen). All media were supplemented with heat-
inactivated 10% fetal bovine serum and penicillin/streptomycin (Invitrogen).
Gastric cell lines were treated with 2 μM of 5-AzaC for 72 h. No mycoplasma
contamination was detected in any of the cultures using a mycoplasma detection
kit. All cell lines were obtained from Yonsei University and authenticated using
short tandem repeat, which was carried out at the Characterized Cell Line Core
Facility, UT MD Anderson Cancer Center.
Quantitative analysis of IGF1 and SFRP mRNA expression. Total RNAs in 5-
AzadC-treated or -untreated cells were extracted using TRIzol solution (Invitrogen,
Carlsbad, CA), and then genomic DNAs were removed by DNAse I (Promega,
Madison, WI, USA) treatment. Total RNAs (5 μg) were reverse-transcribed using a
ﬁrst-strand complementary DNA (cDNA) synthesis kit (Promega) according to the
manufacturer’s speciﬁcations. The cDNAs were subjected to quantitative poly-
merase chain reaction (qPCR) experiments using IGF1, SFRP1, SFRP2, FRZB,
SFRP4, and GAPDH primer sets. The forward and reverse primers were 5′-
GACTCTGAAACCTCAAGCTGTCT-3′ and 5′-GACA-
GATGTAACGAATGGCCAGT-3′ for IGF1, 5′-CAATGCCACCGAAGCCTC-
CAAG-3′ and 5′-CAAACTCGCTGGCACAGAGATG-3′ for SFRP1, 5′-
CTCCAAAGGTATGTGAAGCCTGC-3′ and 5′-CCAGGATGATTTTGG-
TATCTCGG-3′ for SFRP2, 5′- GCTACACAGAAGACCTATTTCCG-3’ and 5′-
CCGTGGAATGTTTACCAGAGAGG-3′ for FRZB, 5′-CTAT-
GACCGTGGCGTGTGCATT-3′ and 5′-GCTTAGGCGTTTACAGTCAACATC-
3′ for SFRP4, and 5′-TTCGACAGTCAGCCGCATCTTCTT-3′ and 5′-
CAGGCGCCCAATACGA CCAAATC-3′ for the GAPDH gene. Quantitative
reverse transcription-PCR (qRT-PCR) was performed in triplicate on a Mas-
tercycler ep realplex system (Eppendorf, Hauppauge, NY, USA). Cycling condi-
tions were 95 °C for 30 s, followed by 40 cycles of 95 °C for 5 s, 62 °C for 30 s, and
72 °C for 20 s. Relative amounts of mRNAs were calculated from the threshold
cycle number using expression levels of GAPDH as an endogenous control.
Western blot analysis. Tissue lysates were isolated using RIPA buffer (50 mM
Tris-HCl pH 8.0, 150 mM NaCl, 2 mM EDTA, 0.5% Na-deoxycholate, 1% NP-40,
0.1% SDS) supplemented with protease inhibitors (Roche, Indianapolis, IN) and
phosphatase inhibitors (Sigma). Then, 20 μg of the protein was separated by
sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) and
transferred onto polyvinylidene diﬂuoride membranes, were immunoblotted using
antibodies against IGF-1Rβ, phospho-IGF-1Rβ, SMAD2/3, phospho-SMAD2/3
(Cell Signaling, Danvers, MA, Cat. No. 3027, 3918, 8685P, and 8828 respectively),
or β-actin (Chemicon, Billerica, MA, Cat. No. MAB1501). Full scan of western
blots are available in Supplementary Fig. 25. Antibodies were diluted in a ratio of
1:200. Proteins of interest were detected with horseradish peroxidase-conjugated
sheep anti-mouse IgG antibody (GE Healthcare, Uppsala, Sweden) and visualized
with the Pierce ECL Western blotting substrate (Thermo Scientiﬁc, Rockford, IL),
according to the provided protocol.
Cell viability assay. Human gastric cell lines were cultured on 12-well plates at a
density of 50,000 cells per well for 24 h and then treated with linsitinib, IGF-1R
inhibitor (Selleck Chemicals, Houston, TX, USA), or equivalent volumes of vehicles
to concentrations for exposure times indicated. The number of viable cells was
counted by Trypan blue dye exclusion using the CountessTM automated cell
counter (Invitrogen). The results were shown as a relative ratio to controls.
Human gastric cancer cell line xenograft model. To establish xenograft tumors,
Hs746T or SNU1 cell lines (1.9 × 106 cells/mouse) were injected subcutaneously
into the upper left ﬂank region of female BALB/c nude mice.
Experimental sample sizes were chosen using power calculations with
preliminary experiments and/or were based on previously described variability in
similar experiments.64 After 10 days, tumor-bearing mice were grouped randomly
(n= 7–9/group) and treated daily oral dosing at 60 mg/kg IGF-1R inhibitor,
linsitinib (OSI-906). Tumor size was measured every other day using calipers.
Tumor volume was estimated using the following formula: L × S2/2 (where L is the
longest diameter and S shortest diameter)65. Animals were maintained under
speciﬁc pathogen-free conditions. All experiments were approved by the Animal
Experiment Committee of Yonsei University.
Immunohistochemistry and image analysis. All tissues were ﬁxed in 10%
neutral-buffered formalin and embedded in parafﬁn wax using standard protocols.
Tissue sections (5 μm) were dewaxed and antigen retrieval was performed in citrate
buffer (pH 6), using an electric pressure cooker set at 120 °C for 5 min. Sections
were incubated for 5 min in 3% hydrogen peroxide to quench endogenous tissue
peroxidase. Primary monoclonal antibodies directed against phospho-Akt1 (pS473)
and phospho-ERK1/2 (pT202/pY204 for ERK1 and pT185/pY187 for ERK3)
(ab8932 and ab50011, Abcam, Cambridge, UK) were diluted with phosphate-
buffered saline in a ratio of 1:100. All tissue sections were counterstained with
hematoxylin, dehydrated, and mounted. MetaMorph 4.6 software (Universal
Imaging Co., Downingtown, PA, USA) was used for computerized quantiﬁcation of
immunostained target protein. The brown stain areas were identiﬁed, and the
intensity was quantiﬁed using the software.
Pyrosequencing. Pyrosequencing was used to evaluate the methylation of IGF1.
Brieﬂy, 500 ng of total DNA from each of the gastric cancer tissue samples was
used for bisulﬁte conversion using the EZ DNA Methylation Gold kit (Zymo
Research, Orange, CA). Then, 1 μl of the bisulﬁte-converted DNA was used in a 20
μl PCR mixture containing primer sets and 2× Master Mix (Doctor Protein, Seoul,
Korea) and ampliﬁed using a GeneAmp PCR system 9700 (Applied Biosystems,
Waltham, MA). For pyrosequencing, forward, reverse, and sequencing primers
were designed with PSQ Assay Design v1.0.6 (Biotage, Kungsgatan, Sweden).
Standard pyrosequencing was then performed. Brieﬂy, 20 μl of PCR product was
immobilized on 3 μl of Streptavidin Sepharose High Performance (GE Health-care
Bio-Sciences, Uppsala, Sweden) and annealed with sequencing primer for 10 min at
80 °C. Finally, the generated pyrograms were analyzed using PyroMark analysis
software (Biotage). PCR condition and sequences for primer sets (Bioneer, Dae-
jeon, Korea) are shown in Supplementary Table 6.
Bisulﬁte sequencing. For bisulﬁte treatment, 1 μg genomic DNAs were denatured
in 0.2 mol/L NaOH. Sodium bisulﬁte (Sigma) and hydroquinone (Sigma) were
added to ﬁnal concentrations of 3.1 mol/L and 0.5 mmol/L, respectively, and the
samples were incubated at 55 °C for 16 h. After puriﬁcation using DNA Clean-Up
System (Promega), the DNA samples were desulfonated in 0.3 mol/L NaOH,
precipitated with ethanol, and resolved with 20 μL Tris-EDTA (TE) buffer. The
modiﬁed DNAs (20 ng) were ampliﬁed by PCR using Taq DNA polymerase (New
England Biolabs, Beverly, MA). Cycling conditions were 94 °C for 5 min, followed
by 35 cycles of 94 °C for 30 s, 56 °C for 30 s, and 72 °C for 30 s, with a ﬁnal
extension of 5 min at 72 °C. The primer sequences for ampliﬁcation of the IGF1
promoter region were 5′-GTTTAGAAGAGGATTTTTATGGGT-3’ (sense, upper
strand) and 5′-CCTAACAAAAATATATCTTTAACTCC-3’ (antisense, upper
strand). The resulting PCR products were cloned into a pGEM-T-easy vector
(Promega) and subjected to sequencing analysis. The primer sequences for bisulﬁte
sequencing, which encompasses the probe region used in pyrosequencing (+130 to
+143 nt. from transcription start site), were 5’-GTGTTTTGTAGA-
TAAATGTGAGGA-3’ (sense, upper strand) and 5’-CTACTAATTTTTCCCAT-
TACTTCTA-3’ (antisense, upper strand).
Data availability. The genomic data that support ﬁndings of this study are
available from the NCBI Gene Expression Omnibus (GEO) under accession
numbers GSE26899 for KUGH, GSE26901 for KUCM, GSE13861 for YUSH,
GSE28541 for MDACC, GSE26253 for SMC, and GSE66229 for ACRG.
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